Xenetic Biosciences, Inc.
XBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.09 | 0.08 | -0.01 |
| FCF Yield | -13.59% | -6.35% | -24.89% | -10.95% |
| EV / EBITDA | -1.41 | -1.75 | 1.21 | 0.01 |
| Quality | ||||
| ROIC | -13.77% | -16.28% | -18.39% | -18.30% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.29 | 0.56 | 1.11 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.68% | 4.27% | 10.32% | 13.57% |
| Free Cash Flow Growth | -71.49% | 61.69% | -48.65% | -46.83% |
| Safety | ||||
| Net Debt / EBITDA | 8.08 | 6.60 | 5.48 | 5.61 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |